Glucose metabolism after pancreas-kidney transplantation

Current Diabetes Reports

Volumn 8, Issue 4, 2008, Pages 310-316

  Diakoff, Elizabeth ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ARGININE; CALCINEURIN INHIBITOR; CYCLOSPORIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCOSE; HEMOGLOBIN A1C; IMMUNOSUPPRESSIVE AGENT; INSULIN; MEGLITINIDE; METFORMIN; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; STEROID; SULFONYLUREA DERIVATIVE; TACROLIMUS; THYMOCYTE ANTIBODY; GLYCOSYLATED HEMOGLOBIN;

CLINICAL TRIAL; DIABETES MELLITUS; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; GLUCOSE TOLERANCE TEST; GLYCEMIC CONTROL; GRAFT DYSFUNCTION; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; KIDNEY FAILURE; KIDNEY PANCREAS TRANSPLANTATION; LOW DRUG DOSE; NONHUMAN; PORTAL VEIN; REVIEW; SURVIVAL RATE; BLOOD; GLUCOSE BLOOD LEVEL; KIDNEY TRANSPLANTATION; METABOLISM; METHODOLOGY; PANCREAS TRANSPLANTATION; PHYSIOLOGY; POSTOPERATIVE COMPLICATION;

BLOOD GLUCOSE; DIABETES COMPLICATIONS; GLUCOSE; GRAFT SURVIVAL; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; KIDNEY TRANSPLANTATION; PANCREAS TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS;

EID: 52649143854     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-008-0055-5     Document Type: Review

References (52)

1. Gruessner AC, Sutherland DER: Pancreas transplant outcomes for United States (US) and non-US cases as reported to the United Network for Organ Sharing (UNOS) and the International Pancreas Transplant Registry (IPTR) as of June 2003. Clin Transplant 2005, 19:433-455.
2. Ojo AO, Meier-Kriesche HU, Hanson JA, et al.: The impact of simultaneous pancreas-kidney transplantation on long-term patient survival. Transplantation 2001, 71:82-90.
3. Tyden G, Bolinder J, Goran S, et al.: Improved survival in patients with insulin-dependent diabetes mellitus and end-stage diabetic nephropathy 10 years after combined pancreas and kidney transplantation. Transplantation 1999, 76:645-648.
4. Matthews DR, Hosker JP, Rudenski AS, et al.: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
5. Matsuda M, DeFronzo RA: Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999, 22:1462-1470.
6. Perseghin G, Caumo A, Sereni LP, et al.: Fasting blood sample-based assessment of insulin sensitivity in kidney-pancreas-transplanted patients. Diabetes Care 2002, 25:2207-2211.
7. Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ: Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003, 3:178-185.
8. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group [no authors listed]. N Engl J Med 1993, 329:977-986.
9. Osei K, Henry ML, O'Dorisio TM, et al.: Physiological and pharmacological stimulation of pancreatic islet hormone secretion in type 1 diabetic pancreas allograft recipients. Diabetes 1990, 39:1235-1242.
10. Landgraf R, Nusser J, Riepl RL, et al.: Metabolic and hormonal studies of type 1 (insulin-dependent) diabetic patients after successful pancreas and kidney transplantation. Diabetologia 1991, 34(Suppl 1):S61-S67.
11. Morel P, Goetz FC, Moudry-Munns K, et al.: Long-term glucose control in patients with pancreatic transplants. Ann Intern Med 1991, 115:694-699.
12. Robertson RP, Sutherland DER, Lanz KJ: Normoglycemia and preserved insulin secretory reserve in diabetic patients 10-18 years after pancreas transplantation. Diabetes 1999, 48:1737-1740.
13. Robertson RP: Consequences on beta-cell function and reserve after long-term pancreas transplantation. Diabetes 2004, 53:633-644.
14. Dieterle CD, Arbogast H, Illner WD, et al.: Metabolic follow-up after long-term pancreas graft survival. Eur J Endocrinol 2007, 156:603-610.
15. Diakoff E, Osei K: Long-term Deterioration of Glucose Tolerance and Development of the Metabolic Syndrome after Pancreas-Kidney Transplantation [poster 2059-P]. Presented at the American Diabetes Association 67th Scientific Sessions. San Diego, CA; June 22-26, 2007.
16. Henry ML, Davies EA, Elkhammas EA, et al.: Pancreatic allograft function as assessed by IMX first-phase insulin assays. Transplant Proc 1994, 26:537.
17. Pfeffer F, Nauck MA, Benz S, et al.: Determinants of a normal (versus impaired) oral glucose tolerance after combined pancreas-kidney transplantation in IDDM patients. Diabetologia 1996, 39:462-468.
18. Christiansen E, Tibell A, Vøolund AA, et al.: Metabolism of oral glucose in pancreas transplant recipients with normal and impaired glucose tolerance. J Clin Endocinol Metab 1997, 82:2299-2307.
19. Srikanta S, Ganda OP, Gleason RE, et al.: Pre-type 1 diabetes. Linear loss of beta cell response to intravenous glucose. Diabetes 1984, 33:717-720.
20. Elmer DS, Hathaway DK, Abdulkarim BA et al.: Use of glucose disappearance rates (kG) to monitor endocrine function of pancreas allografts. Clin Transplant 1998, 12:56-64.
21. Pfeffer F, Nauck MA, Drognitz O, et al.: Postoperative oral glucose tolerance and stimulated insulin secretion: a predictor of endocrine graft function more than 10 years after pancreas-kidney transplantation. Transplantation 2003, 76:1427-1431.
22. Ceriello A: Postprandial hyperglycemia and diabetes complications: is it time to treat? Diabetes 2005, 54:1-7.
23. Battezzati A, Benedini S, Caldara R, et al.: Prediction of the long-term metabolic success of the pancreatic graft function. Transplantation 2001, 71:1560-1565.
24. Luzi L, Secchi A, Facchini F, et al.: Reduction of insulin resistance by combined pancreas-kidney transplantation in type 1 (insulin dependent) diabetic patients. Diabetologia 1990, 33:549-556.
25. Rooney DP, Robertson RP: Hepatic insulin resistance after pancreas transplantation in type 1 diabetes. Diabetes 1996, 45:134-138.
26. Osei K, Cottrell DA, Henry ML, et al.: Minimal model analysis of insulin sensitivity and glucose-mediated glucose disposal in type 1 (insulin-dependent) diabetic pancreas allograft recipients. Diabetologia 1992, 35:676-680.
27. Christiansen E, Vestergaard H, Tibell A, et al.: Impaired insulin-stimulated non-oxidative glucose metabolism in pancreas-kidney transplant recipients. Diabetes 1996, 45:1267-1275.
28. Nankivell BJ, Chapman JR, Bovington KJ, et al.: Clinical determinants of glucose homeostasis after pancreas transplantation. Transplantation 1996, 12:1705-1711.
29. Cottrell DA: Normalization of insulin sensitivity and glucose homeostasis in type 1 diabetic pancreas transplant recipients. J Clin Endocrinol Metab 1996, 81:3513-3519.
30. Paty BW, Harmon JS, Marsh CL, Robertson RP: Inhibitory effects of immunosuppressive drugs on insulin secretion from HIT-T15 cells and Wistar rat islets. Transplantation 2002, 73:353-357.
31. Andreoni KA, Baryman KL, Guidinger MK, et al.: Kidney and pancreas transplantation in the United States, 1996-2005. Am J Transplant 2007, 7:1359-1375.
32. Rizza R, Mandarino LJ, Gerich JE: Cortisol-induced insulin resistance in man: impaired suppression of glucose production and stimulation of glucose utilization due to a post-receptor defect in insulin action. J Clin Endocrinol Metab 1982, 54:131-138.
33. McMahon M, Gerich J, Rizza R: Effects of glucocorticoids on carbohydrate metabolism. Diabetes Metab Rev 1988, 4:17-30.
34. Pozza G, Traeger J, Dubernard JM, et al.: Cyclosporine and glucose intolerance in pancreas transplantation. Lancet 1983, 2:807-808.
35. Luzi L, Sereni LP, Battezzati A, et al.: Metabolic effects of a corticosteroid-free immunosuppressive regimen in recipients of pancreatic transplant. Transplantation 2003, 75:2018-2023.
36. Drachenberg CB, Klassen DK, Weir MR, et al.: Islet cell damage associated with tacrolimus and cyclosporine: morphological features in pancreas allograft biopsies and clinical correlation. Transplantation 1999, 68:396-402.
37. Polastri L, Galbiati F, Bertuzzi F: Secretory defects induced by immunosuppressive agents on human pancreatic betacells. Acta Diabetol 2002, 39:299-233.
38. Yale JF, Chamelian M, Courchesne S, Vigeant C: Peripheral insulin resistance and decreased insulin secretion following cyclosporine A treatment. Transplant Proc 1988, 20:985-988.
39. Heisel O, Heisel R, Balshaw R, Keown P: New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis. Am J Transplant 2004, 4:583-595.
40. Bechstein WO, Malaise J, Saudek F, et al.: Efficacy and safety of tacrolimus compared with cyclosporine microemulsion in primary simultaneous pancreas-kidney transplantation: 1-year results of a large multicenter trial. Transplantation 2004, 77:1221-1228.
41. Secchi A, Malaise J, Caldara R: Metabolic results 3 years after simultaneous pancreas-kidney transplantation. Nephrol Dial Transplant 2005, 20(Suppl 2):ii18-ii24.
42. Dieterle C, Schmauss S, Veitenhasl M, et al.: Glucose metabolism after pancreas transplantation: cyclosporine versus tacrolimus. Transplantation 2004, 77:1561-1565.
43. Diem P, Abid M, Redmon JB, et al.: Systemic venous drainage of pancreas allografts as independent cause of hyperinsulinemia in type 1 diabetic recipients. Diabetes 1990, 39:534-540.
44. Luzi L, Battezzati A, Perseghin GL, et al.: Lack of feed-back inhibition of insulin secretion in denervated human pancreas. Diabetes 1992, 41:1632-1639.
45. Rizza RA, Mandarino LJ, Genest J, et al.: Production of insulin resistance by hyperinsulinemia in man. Diabetologia 1985, 28:70-75.
46. Marangou AG, Weber KM, Boston RE et al.: Metabolic consequences of prolonged hyperinsulinemia in humans: evidence of induction of insulin insensitivity. Diabetes 1986, 35:1383-1389.
47. Boden G, Chen X, Ruiz J, et al.: Insulin receptor downregulation and impaired antilipolytic action of insulin in diabetic patients after pancreas/kidney transplantation. J Clin Endocrinol Metab 1994, 78:657-663.
48. Petruzzo P, Da Silva M, Feitosa LC, et al.: Simultaneous pancreas-kidney transplantation: portal versus systemic venous drainage of the pancreas allografts. Clin Transplant 2000, 14:287-291.
49. Petruzzo P, Laville M, Badet L, et al.: Effect of venous drainage site on insulin action after simultaneous pancreas-kidney transplantation. Transplantation 2004, 12:1875-1879.
50. Petruzzo P, Badet L, Lefrancois N, et al.: Metabolic consequences of pancreatic systemic or portal venous drainage in simultaneous pancreas-kidney transplant recipients. Diabet Med 2006, 23:654-659.
51. Villanueva G, Baldwin D: Rosiglitazone therapy of post-transplant diabetes. Transplantation 2005, 80:1402-1405.
52. Gallwitz B: Glucagon-like peptide-1 as a treatment option for type 2 diabetes and its role in restoring beta-cell mass. Diabetes Technol Ther 2005, 7:651-657.